While remarkable advances have been made in the treatment of pediatric leukemia over the past decades, new therapies are needed for children with advanced solid tumors and high-grade brain tumors who fail standard chemotherapy regimens. Immunotherapy with immune checkpoint inhibitors acting through the programmed cell death-1 (PD-1) pathway has shown efficacy in some chemotherapy-resistant adult cancers, generating interest that these agents may also be helpful to treat certain refractory pediatric malignancies. In this manuscript we review current strategies for targeting the PD-1 pathway, highlighting putative biomarkers and the rationale for investigation of these drugs to treat common pediatric tumors such as sarcoma, neuroblastoma, and high-grade glioma. We summarize the completed and ongoing clinical trial data available, and suggest potential applications for further study.
CITATION STYLE
Wagner, L. M., & Adams, V. R. (2017, April 12). Targeting the PD-1 pathway in pediatric solid tumors and brain tumors. OncoTargets and Therapy. Dove Medical Press Ltd. https://doi.org/10.2147/OTT.S124008
Mendeley helps you to discover research relevant for your work.